亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Oncological Outcomes and Response Rate After Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Network Meta-Analysis Comparing Induction vs. Consolidation Chemotherapy vs. Standard Chemoradiation

医学 结直肠癌 荟萃分析 肿瘤科 新辅助治疗 内科学 诱导化疗 化疗 完全响应 癌症 乳腺癌
作者
Sergei Bedrikovetski,Luke Traeger,Warren Seow,Nagendra Naidu Dudi-Venkata,S. Selva‐Nayagam,Michael Gordon Penniment,Tarik Sammour
出处
期刊:Clinical Colorectal Cancer [Elsevier BV]
卷期号:23 (4): 326-336.e9 被引量:28
标识
DOI:10.1016/j.clcc.2024.06.001
摘要

TNT is now considered the preferred option for stage II-III locally advanced rectal cancer (LARC). However, the prognostic benefit and optimal sequence of TNT remains unclear. This network meta-analysis (NMA) compared short- and long-term outcomes amongst patients with LARC receiving total neoadjuvant therapy (TNT) as induction (iTNT) or consolidation chemotherapy (cTNT) with those receiving neoadjuvant chemoradiation (nCRT) alone. A systematic literature search was performed between 2012 and 2023. A Bayesian NMA was conducted using a Markov Chain Monte Carlo method with a random-effects model and vague prior distribution to calculate odds ratios (OR) with 95% credible intervals (CrI). The surface under the cumulative ranking (SUCRA) curves were used to rank treatment(s) for each outcome. In total, 11 cohorts involving 8360 patients with LARC were included. There was no significant difference in disease-free survival (DFS) and overall survival (OS) amongst the 3 treatments. Compared with nCRT, both cTNT (OR 2.36; 95% CrI, 1.57-3.66) and iTNT (OR 1.99; 95% CrI, 1.44-2.95) significantly improved complete response (CR) rate. Notably, cTNT ranked as the best treatment for CR (SUCRA 0.90) and iTNT as the best treatment for 3-year DFS and OS (SUCRA 0.72 and 0.87, respectively). Both iTNT and cTNT strategies significantly improved CR rates compared with nCRT. cTNT was ranked highest for CR rates, while iTNT was ranked highest for 3-year survival outcomes. However, no other significant differences in DFS, OS, sphincter-saving surgery, R0 resection and postoperative complications were found amongst the treatment groups.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
7秒前
Harding完成签到,获得积分10
8秒前
weako发布了新的文献求助30
10秒前
大大撒发布了新的文献求助10
11秒前
11秒前
OK发布了新的文献求助10
12秒前
Nole的应助被morena采纳,获得10
15秒前
TYW完成签到,获得积分10
17秒前
18秒前
18秒前
科研通AI65的应助被一杯芝士采纳,获得10
19秒前
fantasy的应助被科研通管家采纳,获得10
21秒前
原神大王的应助被科研通管家采纳,获得10
21秒前
大大撒完成签到,获得积分10
21秒前
明理芷巧发布了新的文献求助10
21秒前
iuv发布了新的文献求助10
22秒前
24秒前
OK完成签到,获得积分10
30秒前
30秒前
32秒前
Lucas的应助被明理芷巧采纳,获得10
34秒前
38秒前
一杯芝士发布了新的文献求助10
38秒前
傻傻的冰烟完成签到,获得积分10
39秒前
39秒前
汉堡包的应助被洪亮采纳,获得10
40秒前
weako发布了新的文献求助30
42秒前
43秒前
大脚仙发布了新的文献求助200
44秒前
Un1que完成签到,获得积分10
45秒前
龚洁完成签到 ,获得积分10
46秒前
Shenjinhunag完成签到,获得积分10
46秒前
渡人舟的应助被ytre采纳,获得10
50秒前
科研通AI65的应助被weako采纳,获得30
53秒前
53秒前
今后的应助被weako采纳,获得30
54秒前
爱笑的笑旋完成签到,获得积分10
54秒前
慈祥的水池完成签到,获得积分10
1分钟前
lin完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179766
求助须知:如何正确求助?哪些是违规求助? 9569984
关于积分的说明 21808022
捐赠科研通 7775385
什么是DOI,文献DOI怎么找? 3433123
关于科研通互助平台的介绍 2557167
邀请新用户注册赠送积分活动 2478822